Novel issues in the combined modality treatment of lymphomas
Status of the ZUMA-3 trial of CAR T-cell product KTE-C19 for R/R ALL
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al.
Integrating cellular therapies into clinical practice
Cessation of venetoclax and remaining in remission from CLL?